ong-term follow-up of patients with spinal muscular atrophy Treated with OAV101 in Clinical Trials
- Conditions
- Spinal Muscular AtrophyMedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Registration Number
- EUCTR2021-006781-21-FR
- Lead Sponsor
- ovartis Pharma AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 260
Participants eligible for inclusion in this study must meet all of the following criteria:
1. Received OAV101 IT or OAV101 IV in a Phase I to IIIb clinical trial sponsored by AveXis, Novartis or Novartis Gene Therapies.
2. Patient/Parent/legal guardian willing and able to complete the informed consent process and comply with study procedures.
Are the trial subjects under 18? yes
Number of subjects for this age range: 260
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Score yes” on item 4 or item 5 of the suicidal ideation section of the C-SSRS, if this ideation occurred in the past 6 months, or yes” on any item of the suicidal behavior section, except for the Non-Suicidal Self-Injurious Behavior” (item also included in the suicidal behavior section) if this behavior occurred in the past 2 years.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.